Zobrazeno 1 - 10
of 132
pro vyhledávání: ''
Publikováno v:
OncoTargets and therapy
Approximately 70% of breast cancer (BC) cases are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have acted as star drugs for reversing endocrine t
Publikováno v:
OncoTargets and therapy
Dehui Fu, Chao Li, Yongwang Huang Department of Ear-Nose-Throat (ENT), The Second Hospital of Tianjin Medical University, Tianjin, 300211, People’s Republic of ChinaCorrespondence: Yongwang HuangDepartment of Ear-Nose-Throat, The Second Hospital of
Publikováno v:
OncoTargets and therapy
MET exon 14 skipping variants have been identified as a novel type of oncogenic driver mutations in non-small-cell lung cancer (NSCLC), while the germline MET mutation, especially germline MET exon 14 skipping mutation rarely occurred in NSCLC. Herei
Publikováno v:
OncoTargets and therapy
The emergence of epidermal growth factor receptor (EGFR) exon 20 p.C797S is one of the major resistance mechanisms for osimertinib. However, there are no standard of care for non-small cell lung cancer (NSCLC) patients after acquiring EGFR C797S curr
Publikováno v:
OncoTargets and therapy
Chemotherapy is the mainstay of treatment for advanced small cell esophageal carcinoma (SCEC) characterized by poor prognosis. Preclinical studies demonstrated that apatinib has the potential to enhance the efficacy of conventional chemotherapeutic d
Publikováno v:
OncoTargets and therapy
Saibo Pan,* Shijie Wang,* Wenshan Li, Ying Chai Department of Thoracic Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, People’s Republic of China*These authors contributed equally to this workCor
Publikováno v:
OncoTargets and therapy
Introduction Immuno checkpoint inhibitors (ICIs) including anti-PD-L1 antibody have shown certain therapeutic effects on various cancer types. Here, we reported a case of the patient with resectable non-small cell lung cancer (NSCLC) showing a comple
Autor:
Liping Zhang, Lei Cui, Zhigang Li, Hongyun Lian, Yunze Zhao, Tianyou Wang, Xiaoxi Zhao, Li Zhang, Rui Zhang, Na Li, Honghao Ma, Ying Ying Yang, Dong Wang, Chanjuan Wang, Qing Y Zhang
Publikováno v:
OncoTargets and therapy
Ying Yang,1 Dong Wang,1 Na Li,2 Honghao Ma,1 Hongyun Lian,1 Lei Cui,2 Qing Zhang,2 Xiaoxi Zhao,1 Liping Zhang,1 Yunze Zhao,1 Chanjuan Wang,2 Li Zhang,1 Tianyou Wang,1 Zhigang Li,2 Rui Zhang1 1Beijing Key Laboratory of Pediatric Hematology Oncology; N
Autor:
Liming Guan
Publikováno v:
OncoTargets and Therapy. 13:12811-12827
Background The incidence rate of cervical cancer is the highest in the reproductive tract and is not sensitive to chemotherapy. An appropriate amount of anti-angiogenic agents can reconstruct tumor blood vessels in a short period of time and form vas
Autor:
Jing Zhao, Jinjia Chang, Wenhua Li, Dan Zhu, Guangyi Lin, Qihe Yu, Duo Tong, Dan Huang, Wen Zhang
Publikováno v:
OncoTargets and Therapy. 13:11819-11826
Purpose Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related death. Resistance to chemotherapy is the main reason for the failure of the treatment of mCRC. IL-10 has been reported to decrease after surgery and increase after mCRC